Venture Fund Member Profile
|
 |
 |
Psilos has offices in New York, the San Francisco Bay Area and Santa Fe. We are currently investing from our Psilos III fund, with a primary focus on opportunities in the healthcare services, healthcare information technology, medical device, medical instrumentation and specialty pharmaceutical sectors.
Psilos has established itself as a successful healthcare investor and has demonstrated its ability to effectively identify and analyze attractive investment opportunities, to structure and consummate high-quality transactions and to work with entrepreneurial management teams from company inception to successful liquidity events. We understand entrepreneurial drive and the importance of developing relationships with companies that reinforce management's creative energies.
Psilos seeks investments where we can have a significant positive impact on the strategic development of our portfolio companies, leveraging our broad network of relationships with both strategic and financial investors, corporate partners, investment banks, and industry leaders across the healthcare field. Our team has a multi-disciplinary background and has participated in over 70 healthcare private equity transactions, enabling us to provide meaningful and experienced support to companies around strategy, operations, development of key partnerships, recruitment, marketing, capital formation and merger & acquisition activities.
 |
Jeffrey M. Krauss
Managing Member
Psilos |
Jeffrey joined Psilos in March 2000 with a focus on investments in the healthcare services, healthcare information technology, specialty pharmaceutical and medical instrumentation segments. He currently serves on the Boards of Versamed, Valera Pharmaceuticals, HealthEdge, OneShield.
Prior to joining Psilos, Mr. Krauss was a general partner at Nazem & Company, a New York-based venture capital firm, from 1990 to 2000, where he specialized in investments in the healthcare services and healthcare information technology segments. Prior to joining Nazem & Company, Mr. Krauss was an attorney with the law firm of Simpson, Thacher & Bartlett, where he specialized in private equity transactions and worked extensively on transactions originated by KKR. Prior to that, Mr. Krauss was an auditor with the accounting firm of Ernst & Young. Mr. Krauss is currently a volunteer with the New York City Investment Fund in the Fund’s Healthcare Sector Group. Mr. Krauss performs various services for the Fund, including representing the Fund on the Boards of several portfolio companies.
Mr. Krauss graduated magna cum laude with a Bachelor of Science degree in Accounting from the State University of New York at Albany and he graduated cum laude with a Juris Doctor degree from Harvard Law School . Mr. Krauss is a Certified Public Accountant, licensed in the State of New York , and is also licensed in the State of New York as an Attorney.
Representative Investments
 |
Navitas , Inc. headquartered in Denver, Colorado, is the nation's first company to work with the oncology community, patients and payers to integrate cancer rehabilitation services into the treatment plan for each cancer patient. The mission of Navitas is to improve the health and lives of cancer patients and survivors through an evidence-based, integrated program of rehabilitation and supportive services that address the effects of cancer and cancer treatments and deliver on this promise in a healing and caring environment. The Company's first two locations are in Denver, Colorado and Salt Lake City, Utah. |
 |
OneShield, Inc. provides a comprehensive web-based solution that automates the sale and service of commercial insurance products, including worker's compensation. By offering a fully-hosted solution, OneShield delivers meaningful cost savings through process improvement and self-service to insurance carriers, brokers and agents for all major property, casualty and worker's compensation lines. OneShield helps its customers broaden their geographic distribution and product offerings, while lowering their costs. |
 |
VersaMed Corporation has developed a next generation, computer-based respiratory ventilator, the iVent201, which offers many advantages over comparable mechanical ventilators. These include its small size and portability, its flexible application in multiple clinical settings (including transport and mobile), its ease of use and maintenance, and its low cost (approximately 50% less than competing ventilators). VersaMed offers its FDA-approved products to sub-acute, home care and alternate care markets. (Exited March 2008 via sale to GE Healthcare.) |
 |
Valera Pharmaceuticals, Inc. focuses on the development and the acquisition of novel therapeutics for the urology and endocrinology specialties and is advancing drug delivery with its innovative, state-of-the-art, Hydron Implant Technology. The company recently launched its first FDA-approved product, Vantas, a time-release implantable drug and delivery system, for treatment of metastatic prostate cancer. (Exited December 2006 via sale to Thermo Fisher Scientific, Inc.) |
Jeffrey M. participated in the FundingPost event: New York Early-Stage Venture Capital Conference
on Thursday, May 27, 2010 in NY, Sponsored by Bingham McCutchen LLP
To list your Company on our website and make your profile available to Jeffrey M. and 7,500+ other VCs and Angel Investors, Click Here.
============================================
About FundingPost
For over Twelve Years FundingPost has worked with thousands
of Angel and Venture Capital Investors. We believe that it is
important to reach investors in every medium possible -
both online and offline. We have been directly responsible for
tons of success stories and Millions and Millions of dollars raised.
We look forward to introducing your company to the leading Venture and Angel Investors nationwide.
============================================
|
| Venture Fund Member Profile |
|
Bookmark to del.icio.us
Tweet this Profile
